Solid lipid nanoparticle

Unchained Labs makes another big splash with Big Tuna in gene therapy and vaccines!

Retrieved on: 
Thursday, April 1, 2021
Branches of biology, Biology, Life sciences, Lipids, Solid lipid nanoparticle, Tuna, Vaccine, Gene therapy

PLEASANTON, Calif., April 1, 2021 /PRNewswire/ -- Unchained Labs , the life sciences company that's all about getting researchers the right tool for the job, launched its new gene therapy and vaccine applications on the Big Tuna platform today.

Key Points: 
  • PLEASANTON, Calif., April 1, 2021 /PRNewswire/ -- Unchained Labs , the life sciences company that's all about getting researchers the right tool for the job, launched its new gene therapy and vaccine applications on the Big Tuna platform today.
  • Big Tuna is already the ultimate buffer exchange platform for biologics, and now it can take on buffer exchange, concentration and clean-up of adeno-associated viruses (AAVs) and lipid nanoparticles (LNPs).
  • Big Tuna's new high molecular weight cutoff plates, concentration application and tunable pressure settings make it perfectly dialed in for these molecules.
  • "The use of AAVs and LNPs for gene therapies and vaccines is literally booming," said Taegen Clary, VP of Marketing at Unchained Labs.

Unchained Labs makes another big splash with Big Tuna in gene therapy and vaccines!

Retrieved on: 
Thursday, April 1, 2021
Branches of biology, Biology, Life sciences, Lipids, Solid lipid nanoparticle, Tuna, Vaccine, Gene therapy

PLEASANTON, Calif., April 1, 2021 /PRNewswire/ -- Unchained Labs , the life sciences company that's all about getting researchers the right tool for the job, launched its new gene therapy and vaccine applications on the Big Tuna platform today.

Key Points: 
  • PLEASANTON, Calif., April 1, 2021 /PRNewswire/ -- Unchained Labs , the life sciences company that's all about getting researchers the right tool for the job, launched its new gene therapy and vaccine applications on the Big Tuna platform today.
  • Big Tuna is already the ultimate buffer exchange platform for biologics, and now it can take on buffer exchange, concentration and clean-up of adeno-associated viruses (AAVs) and lipid nanoparticles (LNPs).
  • Big Tuna's new high molecular weight cutoff plates, concentration application and tunable pressure settings make it perfectly dialed in for these molecules.
  • "The use of AAVs and LNPs for gene therapies and vaccines is literally booming," said Taegen Clary, VP of Marketing at Unchained Labs.

Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis

Retrieved on: 
Monday, March 15, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Other Health, Branches of biology, Hepatic stellate cell, Solid lipid nanoparticle, Liver, LNP, Biology, Arcturus Therapeutics

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industrys most robust and expansive lipid nanoparticle (LNP) patent estate, today announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) for the discovery, development and commercialization of LNP-delivered nucleic acid therapeutics directed to previously inaccessible drug targets in hepatic stellate cells to treat liver fibrosis.

Key Points: 
  • Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industrys most robust and expansive lipid nanoparticle (LNP) patent estate, today announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) for the discovery, development and commercialization of LNP-delivered nucleic acid therapeutics directed to previously inaccessible drug targets in hepatic stellate cells to treat liver fibrosis.
  • As longstanding leaders in nucleic acid delivery, Genevant has developed a novel hepatic stellate cell-directed LNP platform to meet this challenge and we are delighted to partner with Takeda to utilize this innovation to develop new treatments for patients suffering from liver fibrosis.
  • Takeda has exclusive rights to Genevants LNP technology for a specified number of selected hepatic stellate cells targets.
  • Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, the industrys most robust and expansive lipid nanoparticle (LNP) patent estate, and decades of experience and expertise in nucleic acid drug delivery and development.

Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results

Retrieved on: 
Monday, March 15, 2021
Lipids, Solid lipid nanoparticle, Branches of biology, Chemistry, Natural sciences, Magnetofection

Beam has made significant progress in the last 12 months, said John Evans, chief executive officer of Beam.

Key Points: 
  • Beam has made significant progress in the last 12 months, said John Evans, chief executive officer of Beam.
  • Beam believes that the proprietary screening method will enable identification of lipid nanoparticles with novel biodistribution and high selectivity for target cells.
  • Using this platform and a proprietary library of cationic lipids, GuideTx has identified a broad array of novel lipid nanoparticle formulations.
  • Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.

Oncology Pharma Extends Its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Human Oncology

Retrieved on: 
Wednesday, February 3, 2021
Health sciences, Liposome, Membrane biology, Health care, Pharmaceutical industry in China, Health, Solid lipid nanoparticle

SAN FRANCISCO, CA, Feb. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in Human Oncology.

Key Points: 
  • SAN FRANCISCO, CA, Feb. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in Human Oncology.
  • NanoSmart's patented, human-derived, anti-nuclear antibody (ANA) binds to necrotic tissue that is present in and around all solid tumors.
  • Lipid nanoparticles, such as liposomes and nanoemulsions, can be used to encapsulate existing and FDA-approved active pharmaceutical ingredients (APIs).
  • For additional information, please contact the Oncology Pharma at:

Global Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems Market Report 2020-2025 with Profiles of Bristol-Myers Squibb Co., GSK, Hofmann-La Roche, Merck & Co., and Novartis

Retrieved on: 
Monday, January 25, 2021
Drug delivery, Medical equipment, Nanomedicine, Health sciences, Medical research, Life sciences, Solid lipid nanoparticle, Emerging technologies, Nanoparticle drug delivery

DUBLIN, Jan. 25, 2021 /PRNewswire/ -- The "Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 25, 2021 /PRNewswire/ -- The "Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems" report has been added to ResearchAndMarkets.com's offering.
  • The report includes an analysis of leading and emerging drug products for each nanoparticle type.
  • The most rapid advances have been made in the application of nanoparticles in drug research and development, drug product formulation, and development of novel drug delivery systems using nanoparticle carriers.
  • Drug formulation and delivery are attracting new players in Europe, and this in turn will contribute to the market's growth.

VECT-HORUS Completes Its €12 Million Fund-raising Operation

Retrieved on: 
Wednesday, January 20, 2021
Medical devices, Finance, Clinical trials, Professional services, Other Health, Radiology, Pharmaceutical, Health, Oncology, Other Professional Services, Nucleic acids, Branches of biology, Molecular biology, Gene expression, Biotechnology, Small interfering RNA, RNA, Solid lipid nanoparticle, Sense

The first round, held in September 2020, raised 6.7 million and a second round in December 2020 added 5.3 million from private investors, bringing the total amount raised in these two rounds to 12 million.

Key Points: 
  • The first round, held in September 2020, raised 6.7 million and a second round in December 2020 added 5.3 million from private investors, bringing the total amount raised in these two rounds to 12 million.
  • The health crisis has for the first time highlighted the enormous therapeutic potential (in terms of vaccination) of messenger RNAs (mRNAs) encapsulated in lipid nanoparticles.
  • In contrast, antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) inhibit the expression of a particular gene and therefore the corresponding protein.
  • The proof of concept of the technology has already been established in animal models using different vectorized molecules.

Unchained Labs sticks it to viruses, launches new mRNA vaccine application on Stunner!

Retrieved on: 
Monday, January 11, 2021
Branches of biology, RNA, Biology, Life sciences, RNA vaccine, Solid lipid nanoparticle, Messenger RNA, Vaccine

PLEASANTON, Calif., Jan. 11, 2021 /PRNewswire/ -- Unchained Labs , the life sciences company that's all about getting researchers the right tool for the job, launched its new mRNA vaccine application on Stunner today.

Key Points: 
  • PLEASANTON, Calif., Jan. 11, 2021 /PRNewswire/ -- Unchained Labs , the life sciences company that's all about getting researchers the right tool for the job, launched its new mRNA vaccine application on Stunner today.
  • Stunner is the only platform that can simultaneously quantify the total amount of mRNA and measure the size distribution of lipid nanoparticles two critical qualities of these novel vaccines.
  • Stunner's super short pathlength for UV/Vis and DLS makes it the perfect tool for measuring both the mRNA concentration and the lipid nanoparticle (LNP) size in these typically cloudy samples.
  • "LNPs need to be just the right size to deliver mRNA for a solid immune response," said Taegen Clary, VP of Marketing at Unchained Labs.

Unchained Labs sticks it to viruses, launches new mRNA vaccine application on Stunner!

Retrieved on: 
Monday, January 11, 2021
Branches of biology, RNA, Biology, Life sciences, RNA vaccine, Solid lipid nanoparticle, Messenger RNA, Vaccine

PLEASANTON, Calif., Jan. 11, 2021 /PRNewswire/ -- Unchained Labs , the life sciences company that's all about getting researchers the right tool for the job, launched its new mRNA vaccine application on Stunner today.

Key Points: 
  • PLEASANTON, Calif., Jan. 11, 2021 /PRNewswire/ -- Unchained Labs , the life sciences company that's all about getting researchers the right tool for the job, launched its new mRNA vaccine application on Stunner today.
  • Stunner is the only platform that can simultaneously quantify the total amount of mRNA and measure the size distribution of lipid nanoparticles two critical qualities of these novel vaccines.
  • Stunner's super short pathlength for UV/Vis and DLS makes it the perfect tool for measuring both the mRNA concentration and the lipid nanoparticle (LNP) size in these typically cloudy samples.
  • "LNPs need to be just the right size to deliver mRNA for a solid immune response," said Taegen Clary, VP of Marketing at Unchained Labs.